Announcements Trials
Browse Landscape

Phase

Phase 2 83Phase 3 17Phase NA 8Phase 1/2 8Phase 1 6Phase 4 2Phase 2/3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

HER2 Positive Breast Cancer 1Breast Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × pyrotinib × Clear all
NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2/3 Active not recruiting
113 enrolled
Breast

Breast Neoplasms

NCT06958627 2025-05-06

any

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Recruiting
964 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡